{"id":"https://openalex.org/W4322769780","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02","title":"Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3K\u03b1 H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3K\u03b1 H1047R-mutant breast cancer models","display_name":"Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3K\u03b1 H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3K\u03b1 H1047R-mutant breast cancer models","publication_year":2023,"publication_date":"2023-03-01","ids":{"openalex":"https://openalex.org/W4322769780","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs22-p4-08-02","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057570241","display_name":"Loredana Puca","orcid":"https://orcid.org/0000-0002-0895-1519","observed_orcids":["https://orcid.org/0000-0002-0895-1519"]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Loredana Puca","raw_affiliation_strings":["1Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013385271","display_name":"Michele S. Dowless","orcid":"https://orcid.org/0009-0008-4148-0473","observed_orcids":["https://orcid.org/0009-0008-4148-0473"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michele S. Dowless","raw_affiliation_strings":["2Loxo@Lilly, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Loxo@Lilly, Indianapolis, Indiana","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021562008","display_name":"Carmen M. Perez-Ferreiro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carmen M. Perez-Ferreiro","raw_affiliation_strings":["3Eli Lilly and Company"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Eli Lilly and Company","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112069957","display_name":"Mar\u00eda Jes\u00fas Ortiz-Ruiz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128228","display_name":"Eli Lilly (Spain)","ror":"https://ror.org/033911096","country_code":"ES","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210128228"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Maria Jesus Ortiz-Ruiz","raw_affiliation_strings":["4Eli Lilly and Company, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Eli Lilly and Company, Madrid, Spain","institution_ids":["https://openalex.org/I4210128228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071061160","display_name":"Gregory P. Donoho","orcid":"https://orcid.org/0009-0007-8865-5093","observed_orcids":["https://orcid.org/0009-0007-8865-5093"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory P. Donoho","raw_affiliation_strings":["5Loxo@Lilly, Indianpolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Loxo@Lilly, Indianpolis, Indiana","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022743245","display_name":"Andrew R. Capen","orcid":"https://orcid.org/0009-0002-2506-3684","observed_orcids":["https://orcid.org/0009-0002-2506-3684"]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Capen","raw_affiliation_strings":["6Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112905296","display_name":"Lysiane Huber","orcid":"https://orcid.org/0009-0003-3545-2963","observed_orcids":["https://orcid.org/0009-0003-3545-2963"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lysiane Huber","raw_affiliation_strings":["7Eli Lilly & Company"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Eli Lilly & Company","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029200785","display_name":"Sarah M. Bogner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sarah M. Bogner","raw_affiliation_strings":["8Eli Lilly and Company"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Eli Lilly and Company","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087555097","display_name":"Dongling Fei","orcid":"https://orcid.org/0009-0002-9543-6378","observed_orcids":["https://orcid.org/0009-0002-9543-6378"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dongling Fei","raw_affiliation_strings":["9Eli Lilly and Company, Zionsville, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Eli Lilly and Company, Zionsville, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041068728","display_name":"Jason R. Manro","orcid":"https://orcid.org/0009-0006-4046-1989","observed_orcids":["https://orcid.org/0009-0006-4046-1989"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason R. Manro","raw_affiliation_strings":["10Preclinical/Drug Discovery Statistics - Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Preclinical/Drug Discovery Statistics - Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112561677","display_name":"Chun Ping Yu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Chun Ping Yu","raw_affiliation_strings":["11Eli Lilly China Research and Development Center, Shanghai"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Eli Lilly China Research and Development Center, Shanghai","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Wei Guo Xu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wei Guo Xu","raw_affiliation_strings":["12Eli Lilly China Research and Development Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Eli Lilly China Research and Development Center","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rui Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rui Wang","raw_affiliation_strings":["13Loxo@Lilly, Stamford, NEW YORK, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Loxo@Lilly, Stamford, NEW YORK, New York","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shuang Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shuang Chen","raw_affiliation_strings":["14Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mark A. Hicks","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A. Hicks","raw_affiliation_strings":["15Loxo@Lilly, Stamford, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"15Loxo@Lilly, Stamford, New York, New York","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076821573","display_name":"Parisa Zolfaghari","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Parisa Zolfaghari","raw_affiliation_strings":["16Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"16Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080907888","display_name":"Andrew L. Faber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Faber","raw_affiliation_strings":["17Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"17Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108694174","display_name":"Raymond Gilmour","orcid":"https://orcid.org/0009-0000-6753-0071","observed_orcids":["https://orcid.org/0009-0000-6753-0071"]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raymond Gilmour","raw_affiliation_strings":["18Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"18Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009454874","display_name":"Monica D. Ramstetter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monica D. Ramstetter","raw_affiliation_strings":["19Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"19Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109425834","display_name":"Matthew T. Chang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew T. Chang","raw_affiliation_strings":["20Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"20Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012974974","display_name":"Mar\u0131\u0301a Jos\u00e9 Lallena","orcid":"https://orcid.org/0000-0002-6617-798X","observed_orcids":["https://orcid.org/0000-0002-6617-798X"]},"institutions":[{"id":"https://openalex.org/I4210128228","display_name":"Eli Lilly (Spain)","ror":"https://ror.org/033911096","country_code":"ES","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210128228"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Maria Jose Lallena","raw_affiliation_strings":["21Eli Lilly and Company, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"21Eli Lilly and Company, Madrid, Spain","institution_ids":["https://openalex.org/I4210128228"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031917355","display_name":"Xuequian Gong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xuequian Gong","raw_affiliation_strings":["22Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"22Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068193017","display_name":"David Michael Hyman","orcid":"https://orcid.org/0000-0001-8150-9762","observed_orcids":["https://orcid.org/0000-0001-8150-9762"]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Hyman","raw_affiliation_strings":["23Loxo@Lilly, Stamford, Stamford, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"23Loxo@Lilly, Stamford, Stamford, Connecticut","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091455253","display_name":"Lillian Mary Smyth","orcid":"https://orcid.org/0000-0002-0986-9285","observed_orcids":["https://orcid.org/0000-0002-0986-9285"]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lillian M. Smyth","raw_affiliation_strings":["24Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"24Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015825916","display_name":"Barbara J. Brandhuber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara J. Brandhuber","raw_affiliation_strings":["25Loxo@Lilly, Stamford, Colorado"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"25Loxo@Lilly, Stamford, Colorado","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053532132","display_name":"Barry S. Taylor","orcid":"https://orcid.org/0000-0002-3355-9471","observed_orcids":["https://orcid.org/0000-0002-3355-9471"]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barry S. Taylor","raw_affiliation_strings":["26Loxo@Lilly, Stamford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"26Loxo@Lilly, Stamford, CT, USA","institution_ids":["https://openalex.org/I4210132618"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5014243449","display_name":"Anke Klippel","orcid":"https://orcid.org/0009-0009-5979-3299","observed_orcids":["https://orcid.org/0009-0009-5979-3299"]},"institutions":[{"id":"https://openalex.org/I4210132618","display_name":"Loxo Oncology at Lilly (United States)","ror":"https://ror.org/03abe5304","country_code":"US","type":"company","lineage":["https://openalex.org/I4210132618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anke Klippel","raw_affiliation_strings":["27Loxo@Lilly, Stamford, CT, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"27Loxo@Lilly, Stamford, CT, New York","institution_ids":["https://openalex.org/I4210132618"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"5_Supplement","first_page":"P4","last_page":"08"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8659999966621399},{"id":"https://openalex.org/keywords/brain-penetration","display_name":"brain penetration","score":0.7310000061988831},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7450000047683716},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.9409999847412109},{"id":"https://openalex.org/keywords/imlunestrant","display_name":"imlunestrant","score":0.9559999704360962},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.5659999847412109},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.6579999923706055},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.7089999914169312},{"id":"https://openalex.org/keywords/combination-index","display_name":"combination index","score":0.6769999861717224},{"id":"https://openalex.org/keywords/synergistic-effect","display_name":"synergistic effect","score":0.3709999918937683},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.7009999752044678}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7334751486778259},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6544747352600098},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5774385929107666},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.5387391448020935},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45906761288642883},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40772372484207153},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40095505118370056},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3682328462600708},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1384141445159912},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.10773676633834839},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09885117411613464},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs22-p4-08-02","doi":"https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8399999737739563}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4322774053","https://openalex.org/W4411288204","https://openalex.org/W4200536844","https://openalex.org/W4411289906","https://openalex.org/W4396591174","https://openalex.org/W4322775362","https://openalex.org/W4393989287","https://openalex.org/W4411289938","https://openalex.org/W4411289451","https://openalex.org/W4396590583"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Phosphoinositide":[2],"3-kinase":[3],"alpha":[4],"(PI3K\u03b1)":[5],"H1047R":[6,62,82,159,589],"mutations":[7],"are":[8],"activating":[9],"oncogenic":[10],"events":[11],"that":[12,64],"occur":[13],"in":[14,67,95,108,116,123,137,147,156,172,196,238,256,262,268,280,315,324,330,340,358,366,390,420,429,433,440,443,454,467,478,484,498,591,599],"~15%":[15],"of":[16,132,210,333,345,356,369,400,494,595,609],"breast":[17,100,139,166,437,455,603],"cancers":[18,456],"(BC).":[19],"Early":[20],"generation":[21],"PI3K\u03b1":[22,30,61,81,85,98,246,284,459,588,601],"inhibitors":[23],"target":[24],"both":[25,468],"wild-type":[26],"(WT)":[27],"and":[28,49,56,86,90,146,163,294,323,327,380,422,426,442,470,486,585],"mutant":[29,160,287,480,583],"and,":[31],"as":[32,73,277,279,416,481,483],"a":[33,74,174,269,297,341,417,434],"result,":[34],"their":[35],"efficacy":[36,131,237,362],"may":[37],"be":[38],"limited":[39],"by":[40],"on-target":[41],"WT":[42,84],"PI3K\u03b1-mediated":[43],"toxicities,":[44],"including":[45],"hyperglycemia,":[46],"skin":[47],"rash,":[48],"diarrhea.":[50],"LOXO-783":[51,72,111,133,216,250,308,334,347,370,401,412,446,474,495],"is":[52,65,77,475,503],"an":[53,253,281,312],"oral,":[54],"potent":[55],"highly":[57,78,582],"mutant-selective,":[58],"brain-penetrant":[59,586],"allosteric":[60,587],"inhibitor":[63,590],"currently":[66],"phase":[68,491],"1":[69,492],"testing.":[70],"Preclinically,":[71],"single":[75,418,462],"agent":[76,419],"selective":[79,584],"for":[80],"over":[83],"other":[87],"PI3K":[88],"isoforms,":[89],"induces":[91],"single-agent":[92],"tumor":[93,120,343,354,372],"regressions":[94],"ER+,":[96],"HER2-":[97,162,283],"H1047R-mutant":[99,247,602],"cancer":[101,140,167,438,604],"models":[102,329,605],"without":[103],"causing":[104],"hyperglycemia":[105],"or":[106,227,463,497],"increases":[107],"plasma":[109],"insulin/C-peptide.":[110],"also":[112,251,290,476],"demonstrates":[113],"brain":[114,124],"penetration":[115],"vivo":[117,148,197],"with":[118,134,217,258,335,348,376,382,402,431,452,500,593],"dose-dependent":[119],"growth":[121],"inhibition":[122,224,232,320],"metastasis":[125],"models.":[126,141,168,392,489],"Here":[127],"we":[128],"report":[129],"the":[130,180,195,199,207,211,243,367,397,458,610],"SOC":[135,403,453],"treatments":[136,598],"preclinical":[138,600],"Methods":[142],"Cell":[143],"proliferation":[144,240],"assays":[145,241],"studies":[149,407],"to":[150,205,273,408],"evaluate":[151,206],"combination":[152,171,175,212,257,430,499,592],"effects":[153,449],"were":[154,266],"performed":[155],"various":[157],"PI3Ka":[158],"HR+,":[161,244,282],"triple":[164,435,471],"negative":[165,436,472],"For":[169,194],"each":[170],"vitro,":[173],"index":[176],"(CI)":[177],"based":[178],"on":[179,302],"Loewe":[181],"Additivity":[182],"Method":[183,202],"was":[184,203,363,374,413,427],"calculated":[185],"(CI>2":[186],"antagonism,":[187],"0.5>CI<":[188],"2":[189],"additivity,":[190],"CI<":[191],"0.5":[192],"synergy).":[193],"studies,":[198],"Bliss":[200],"Independence":[201],"used":[204],"statistical":[208],"significance":[209],"effects.":[213],"Results":[214],"Combining":[215],"either":[218],"fulvestrant":[219],"(FUL;":[220],"CI":[221],"at":[222,230,318],"50%":[223,231,319],"=":[225,233,321],"0.28)":[226],"imlunestrant":[228,338],"(CI":[229,317],"0.43)":[234],"showed":[235,352],"increased":[236],"cell":[239],"using":[242],"HER2-,":[245],"T47D":[248,270,325,359],"model.":[249],"demonstrated":[252,311],"additive":[254,313,398,428,448],"effect":[255,314,399],"these":[259,406],"endocrine":[260],"therapies":[261,502],"vivo.":[263,331,444],"Similar":[264,361],"results":[265,389],"observed":[267,365,387],"model":[271,288,439],"engineered":[272],"express":[274],"ESR1":[275,292,479],"D538G,":[276],"well":[278,482],"double":[285,464],"in-cis":[286,465],"(H1047R/D350G)":[289],"harboring":[291,457],"D538G":[293],"derived":[295],"from":[296],"patient":[298],"who":[299],"had":[300],"progressed":[301],"prior":[303],"letrozole":[304],"plus":[305,309,337,350,378,384],"taselisib.":[306],"Moreover,":[307],"abemaciclib":[310,336,349,377,383,485],"vitro":[316,441],"0.61),":[322],"xenograft":[326],"PDX":[328,391],"Combinations":[332],"resulted":[339],"mean":[342,353],"regression":[344,355,373],"\u201348.1%;":[346],"FUL":[351],"\u201343.9%":[357],"xenografts.":[360],"not":[364],"absence":[368],"(mean":[371],"\u20137.3%":[375],"imlunestrant,":[379],"3.2%":[381],"FUL).":[385],"We":[386],"comparable":[388],"These":[393],"data":[394],"collectively":[395],"demonstrate":[396],"treatments.":[404],"Extending":[405],"additional":[409],"treatment":[410],"settings,":[411],"similarly":[414],"efficacious":[415,477],"abemaciclib-resistant":[421],"abemaciclib/FUL":[423,487],"double-resistant":[424,488],"models,":[425],"paclitaxel":[432],"Conclusions":[445],"shows":[447],"when":[450],"combined":[451],"H1047R-mutation":[460],"(as":[461],"mutations)":[466],"HR+":[469],"settings.":[473],"A":[490,580],"trial":[493],"alone":[496],"anticancer":[501],"ongoing":[504],"(PIKASSO-01;":[505],"NCT05307705).":[506],"Citation":[507],"Format:":[508],"Loredana":[509],"Puca,":[510],"Michele":[511],"S.":[512,575],"Dowless,":[513],"Carmen":[514],"M.":[515,528,566,569],"Perez-Ferreiro,":[516],"Maria":[517,560],"Jesus":[518],"Ortiz-Ruiz,":[519],"Gregory":[520],"P.":[521],"Donoho,":[522],"Andrew":[523,550],"Capen,":[524],"Lysiane":[525],"Huber,":[526],"Sarah":[527],"Bogner,":[529],"Dongling":[530],"Fei,":[531],"Jason":[532],"R.":[533],"Manro,":[534],"Chun":[535],"Ping":[536],"Yu,":[537],"Wei":[538],"Guo":[539],"Xu,":[540],"Rui":[541],"Wang,":[542],"Shuang":[543],"Chen,":[544],"Mark":[545],"A.":[546],"Hicks,":[547],"Parisa":[548],"Zolfaghari,":[549],"Faber,":[551],"Raymond":[552],"Gilmour,":[553],"Monica":[554],"D.":[555],"Ramstetter,":[556],"Matthew":[557],"T.":[558],"Chang,":[559],"Jose":[561],"Lallena,":[562],"Xuequian":[563],"Gong,":[564],"David":[565],"Hyman,":[567],"Lillian":[568],"Smyth,":[570],"Barbara":[571],"J.":[572],"Brandhuber,":[573],"Barry":[574],"Taylor,":[576],"Anke":[577],"Klippel.":[578],"LOXO-783:":[579],"potent,":[581],"standard":[594],"care":[596],"(SOC)":[597],"[abstract].":[606],"In:":[607],"Proceedings":[608],"2022":[611,617],"San":[612,620],"Antonio":[613],"Breast":[614],"Cancer":[615,626],"Symposium;":[616],"Dec":[618],"6-10;":[619],"Antonio,":[621],"TX.":[622],"Philadelphia":[623],"(PA):":[624],"AACR;":[625],"Res":[627],"2023;83(5":[628],"Suppl):Abstract":[629],"nr":[630],"P4-08-02.":[631]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-03-03T00:00:00"}